|
|
PRESS RELEASE
Acticor Biotech announces the appointment of
Patricia Zilliox to the Board of Directors
as an independent director
Paris, France, February 06, 2023 – 06:00 pm CET ACTICOR BIOTECH ISIN: FR0014005OJ5 ALACT, a
clinicalstage biotechnology company focused on the development of innovative drugs for the
treatment of cardiovascular... Lire le communiqué |
|
| |
|
| |
|
|
COMMUNIQUE DE PRESSE
Acticor Biotech fait le point sur les discussions
réglementaires avec la FDA américaine
Paris, France, le 23 décembre 2022 – 8h00 CET ACTICOR BIOTECH ISIN : FR0014005OJ5 – ALACT,
entreprise de biotechnologie au stade clinique spécialisée dans le développement de médicaments
innovants pour le traitement des urgences cardiovasculaires,... Lire le communiqué |
|
| |
|
| |
|
|
University of Birmingham News Release November 22, 2022
Limited clinical access available
World’s first clinical trial to test new drug glenzocimab for heart attacks
Partnership between the University of Birmingham and Acticor Biotech will see patients with heart
attacks treated with glenzocimab, a promising new class of drug for the... Lire le communiqué |
|
| |
|
| |
|
|
PRESS RELEASE
Acticor Biotech strengthens
its financial structure
Issuance of convertible bonds into shares for an amount of €3.9 M to
historical shareholders
Issuance of simple bonds with attached warrants to a new French investor
for €2.0 M
Paris, France, October 18, 2022 8:00 a.m. CEST Acticor Biotech Euronext Growth Paris ISIN... Lire le communiqué |
|
| |
|
| |
|
|
COMMUNIQUE DE PRESSE
Acticor Biotech renforce
sa structure financière
• Émission d’obligations convertibles en actions pour un montant de 3,9 M€
auprès d’actionnaires historiques
• Émission d’obligations simples avec bons de souscription d’actions attachés
auprès d’une société d’investissement française à... Lire le communiqué |
|
| |
|
| |
|
|
PRESS RELEASE
Acticor Biotech announces the enrollment of
the first US patient in its Phase 2/3 study ACTISAVE
for the treatment of stroke
Paris, France, September 26, 2022 – 06:00pm CEST ACTICOR BIOTECH ISIN: FR0014005OJ5 ALACT,
a clinicalstage biotechnology company developing innovative drugs for the treatment of
cardiovascular emergencies, particularly... Lire le communiqué |
|
| |
|
| |
|
|
COMMUNIQUE DE PRESSE
COMMUNIQUE DE PRESSE
Disclosure of the total number of voting rights and shares
as of August 31, 2022
Paris, France, September 9, 2022 ACTICOR BIOTECH ISIN : FR0014005OJ5 – ALACT, a clinical... Lire le communiqué |
|
| |
|
| |
